Detailed explanation of possible side effects and common complications of Quizartinib

Quizartinib is an oral FLT3 inhibitor, mainly used to treat patients with acute myeloid leukemia (AML) with FLT3-ITD mutations. As a second-generation targeted drug, it has high selectivity and efficacy in inhibiting the FLT3 signaling pathway. It is often used in patients with relapsed or refractory AML, or in the maintenance treatment phase after combined chemotherapy. Although quizartinib has shown positive performance in prolonging disease-free survival and overall survival, a series of side effects and complications may still occur during clinical use, and patients need to pay close attention during the treatment process.

1. Classification and frequency of common side effects

According to the results of international multi-centerIII phase clinical trials (such asQuANTUM-R and QuANTUM-First), the most common adverse reactions of quizartinib include:

1. Gastrointestinal reactions

Nausea, vomiting, and diarrhea: are one of the earliest side effects, often occurring in the early stages of medication. It is usually mild to moderate and can be relieved by symptomatic treatment, such as antiemetics (such as ondansetron) or antidiarrheals (such as loperamide).

Decreased appetite: Some patients experience decreased desire to eat and weight loss, and require enhanced nutritional support.

2. Abnormality of the hematopoietic system

Neutropenia, thrombocytopenia, and anemia: Because Quizartinib acts on bone marrow proliferating cells, it inhibits the hematopoietic system. Such adverse reactions are common in patients receiving chemotherapy at the same time. If bone marrow suppression of grade 3 or above occurs, suspension of medication or dose adjustment should be considered.

Febrile neutropenia: This is one of the more serious immune complications and may increase the risk of infection, especially when leukopenia combined with fever requires immediate anti-infective treatment.

3. Electrolyte imbalance

Hypokalemia and hypomagnesemia: may aggravateQT the risk of prolongation of the interval. Serum electrolytes need to be monitored regularly during medication, and potassium and magnesium should be supplemented appropriately. Although these side effects are controllable, if not treated in time, they may lead to serious problems such as arrhythmia.

4. QTinterval prolongation (QTc prolongation)

This is one of the most concerning and serious side effects of quizartinib. The mechanism may be related to the drug's inhibition of myocardial potassium channels. QT If prolongation of the QT interval is not detected and intervened in time, it may lead to torsade de pointes, and in severe cases, sudden death. Therefore, all patients taking quizartinib require electrocardiogram (ECG) monitoring before and during treatment, especially if other drugs that prolong QT or electrolyte imbalance are used in combination.

2. Serious adverse reactions and treatment strategies

Although adverse effects in most patients are mild to moderate and reversible, some individuals may develop serious complications:

1. Arrhythmia

If the QTcinterval exceeds 500ms or extends beyond baseline by more than 60ms, the drug should be discontinued immediately and the electrocardiogram should be evaluated. If accompanied by symptoms such as obvious palpitations, syncope, and chest pain, it is necessary to consider suspending treatment and referring to a cardiac specialist.

2. Severe infection

Severe infections such as pneumonia and sepsis under immunosuppression also require special attention. In particular, patients with neutropenia are prone to rapid progression without early symptoms of typical infection, and require preventive antibiotics and intensive monitoring.

3. Abnormal liver function

A small number of patients may experience elevated levels of ALT and AST during treatment, indicating liver cell damage. Most of them are 1~2 grade elevations, which do not affect treatment. If the level rises to level 3 or above or is combined with an increase in bilirubin, drug correlation needs to be evaluated and a decision should be made as to whether to discontinue the drug.

3. Suggestions on prevention and monitoring of side effects

In order to ensure the safety and efficacy of medication, patients and doctors should strengthen the following monitoring before, during and after medication:

Electrocardiogram monitoring: before the first dose, on 7 days, 14 days and once a month thereafter, or immediately if any heart rhythm symptoms occur;

Electrolyte testing: especially blood potassium and blood magnesium, if they are below the normal lower limit, they need to be replenished in time;

Routine blood examination: monitor blood cell levels weekly to prevent severe bone marrow suppression;

Liver and kidney function: Evaluate every2~4 weeks to monitor drug metabolism status;

Co-administration of medications: Avoid combination with other QT prolonging drugs or CYP3A4 strong inhibitors to reduce the risk of drug interactions.

4. Individualized treatment suggestions and life guidance

Dose management: The common dose of quizartinib is 60mg per day, but for patients with prolonged QT interval or poor tolerance, the dose may be adjusted to 40mg or even discontinued;

Time and method of administration: Take once a day orally. It is recommended to swallow it after a meal or with water. Avoid using it on an empty stomach;

Lifestyle adjustment: regular work and rest, avoid overwork and mood swings, supplement potassium, magnesium and other elements in the diet;

Patient education: Clarify how to identify early symptoms of side effects, such as palpitations, dizziness, fatigue, bleeding tendencies, etc. Timely medical treatment can reduce the incidence of complications.

Quizatinib, as a new generation of drugs targeting FLT3-ITD mutations, has significant clinical efficacy and brings new hope for survival to patients with relapsed and refractory AML. However, it is also accompanied by a certain degree of side effects during the treatment, especially QT interval prolongation, electrolyte imbalance and bone marrow suppression are the most common. Through standardized monitoring processes, early identification of adverse reactions, individualized dose adjustment, and patient education, most side effects are controllable and reversible. It is recommended that patients use this drug under the guidance of a professional hematologist and conduct evaluations on time to maximize the safety and long-term efficacy of the treatment.

Reference materials:https://www.drugs.com/